Amazon.com, Inc. (AMZN) — closed signal from January 10, 2026
Partial Published before the outcome was known, scored automatically when the window closed on April 10, 2026.
Predicted vs. what happened
What happened
Reached 4% of the predicted growth at its peak, without hitting the target.
The thesis — published January 10, 2026
Amazon has a near-term boost from its expanding services, and steady income from its cloud and advertising businesses keeps the investment case grounded for the next few months. The pharmacy offering of a popular weight-loss pill on Jan 10 adds a new growth angle, but the stock moved up quickly so buying now is risky; prefer waiting for dips.
Primary drivers
- Pharmacy offering of weight-loss pill supports services growth story
- AWS and ad sales provide reliable, stabilizing revenue
- Large company size makes it easier for investors to trade in and out
- Buying on pullbacks lowers risk after fast price moves
How it played out
AMZN: the target was not reached
Lyra published AMZN at 247.38 on 2026-01-10 with a short-term thesis for 14% expected growth. The thesis pointed to Amazon's pharmacy offering of a weight-loss pill, steady cloud and advertising income, large-company liquidity, and waiting for pullbacks after a fast move.
Inside the window, AMZN peaked at 248.94 on 2026-01-12, a 0.6% gain. It stayed below the 282.01 target and never reached it. By 2026-04-10, it ended at 238.38. The thesis did not play out on price.
What happened during the window
On 2026-02-05, Amazon reported fourth-quarter results and discussed a large capital-spending plan for 2026. On 2026-04-09, The Wall Street Journal reported that Eli Lilly's weight-loss pill became available in the U.S., with access through Amazon Pharmacy among other platforms.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.